US consulting services
|
US regulatory pathway is very complex. While the rewards of having an approved product on American market are obvious - it's share of all international pharmaceutical sales is around 50%, one needs to understand all the intricacies of the application process. Cromos Pharma’s CEO, Dr. Bogin and members of our Advisory board have vast experience in biopharma industry and regulatory activities in the US. We are ready to provide consultations related to US pharmaceutical market and FDA registration, from review of your IP strength and preclinical data, to guiding you through IND application and NDA filing. If you are interested in this service, just This e-mail address is being protected from spambots. You need JavaScript enabled to view it or call Dr Vladimir Bogin. |
News and messages from CEO,
Dr Vladimir Bogin
12.01.2012 |
Cromos Pharma has participated in the conference on clinical trials in emerging markets in Tel-Aviv, Israel on 11 January 2012. [...] |
05.01.2012 |
Meet Cromos Pharma's CEO, Dr. Vladimir Bogin at the 30th JP Morgan Healthcare Conference in San Francisco, CA on 9-12 January 2012. [...] |
14.12.2011 |
Cromos Pharma published a white paper with review of Russian clinical trials market in 2011. [...] |
28.10.2011 |
Cromos Pharma's CEO, Dr. Vladimir Bogin has participated in the annual Rusnanotech forum in Moscow, Russia on 25-28 October 2011 . [...] |
27.09.2011 |
Meet us at 17th Annual International Partnering Conference BIO-Europe 2011 in Duesseldorf, Germany on 31 October - 02 November 2011. [...] |
